Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
ConclusionsErenumab is cost-effective versus topiramate as a preventive treatment for EM and versus placebo for patients with CM from the perspective of the Spanish National Health System.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Chronic Pain | Clinical Trials | Headache | Migraine | Neurology | Pain | Spain Health | Study | Topamax